menu
    • menu
    [{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Ildong Pharmaceutical \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Ildong Pharmaceutical \/ Ildong"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IDG16177","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Ildong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ildong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ildong Pharmaceutical \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ildong Pharmaceutical \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Ildong Pharmaceutical

    Menu

    Ildong Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lasmiditan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ildong’s Migraine Drug Patent Blocks Latecomer’s Market Entry

                            Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

                            Brand Name : Reyvow

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2022

                            Lead Product(s) : Lasmiditan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VHH Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applic...

                            Details : Under the terms of the agreement, Ildong will license a suite of Twist’s VHH antibody libraries for a period of three years and will use the libraries to conduct research and development activities.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 30, 2022

                            Lead Product(s) : VHH Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDG16177

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany

                            Details : A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated in Germany.

                            Brand Name : IDG16177

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2021

                            Lead Product(s) : IDG16177

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ildong Pharmaceutical

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDG-16177

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec and Ildong to collaborate with development projects on INDiGO platform

                            Details : Under the terms of the agreement, Evotec's experts in Integrated development solutions will accelerate the development of Ildong's projects with services from Evotec's comprehensive INDiGO platform.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 31, 2020

                            Lead Product(s) : IDG-16177

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth